Transdermal Diagnostics Receives SBRI Healthcare Grant for Revolutionary Diabetes Monitoring Technology.
Transdermal Diagnostics (TD) has been awarded a significant grant from the SBRI (Small Business Research Initiative) Healthcare to support the development of its diabetes monitoring technology. This grant marks a significant milestone for the company as it embarks on a new approach to revolutionize the lives of children and young adults grappling with diabetes through TD’s innovative needle-free continuous glucose monitoring (CGM) wearable.
Continuous glucose monitoring (CGM) represents a paradigm shift in diabetes care, offering real-time insights into blood glucose levels around the clock. Traditionally, CGM has involved the use of invasive devices, necessitating needles or tube insertion under the skin that can cause discomfort, pain, and other skin-related issues.
Transdermal Diagnostics is committed to changing this landscape. The non-invasive monitor is a wearable, combining a daily disposable skin patch with a re-chargeable electronic controller, that is user-friendly, discreet, and pain-free. Leveraging state-of-the-art technology, TD’s device seamlessly transmits glucose level data to the user's smartphone via a specialized mobile app.
The SBIR-funded project encompasses workshops, surveys, and focus groups to gather invaluable feedback from users, enabling TD to refine and optimise its product design. By actively engaging with young individuals and their caregivers, TD will ensure that its technology is tailored to the specific requirements of its key stakeholders, fostering trust and confidence in the innovative solution.
TD is particularly looking forward to exploring the potential of the wearable “skin-patch” monitor for children and young people living with Type 1 diabetes. Their insights will inform the design of a 'first in human' study, laying the groundwork for the widespread adoption of this ground-breaking technology.
In line with TD’s commitment to enhancing the lives of individuals with diabetes, the company has established collaborations with recognised experts in the field, including Prof. Julian Hamilton-Shield, Professor of Diabetes and Metabolic Endocrinology at the University of Bristol and honorary consultant at Bristol Royal Hospital for Children (BRHC). Together, we aim to develop a painless, user-friendly, and cost-effective CGM system that meets the evolving needs of people living with diabetes.
📹 Watch Now: Dive into the Future of Diabetes Monitoring with Transdermal Diagnostics 📹
Join Luca Lipani, co-founder and CEO of Transdermal Diagnostics, as he discusses the next generation of non-invasive, wearable devices that our team is tirelessly working on. Witness firsthand how our innovative solutions are poised to revolutionize diabetes management and empower individuals to live healthier, more fulfilling lives. Together, we can make a difference.
This work was commissioned and funded by SBRI Healthcare. SBRI Healthcare is an Accelerated Access Collaborative (AAC) initiative, in partnership with the Health Innovation Network. The views expressed in the publication are those of the author(s) and not necessarily those of SBRI Healthcare or its stakeholders.
